Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.

What It Covers

The paper reports a study of Terlipressin and Angiotensin II, published as a systematic review.

Vasodilatory shock is the most common type of shock.

Catecholamine vasopressors are the cornerstone of hemodynamic therapy but carry risks.

Angiotensin II (AT2) was recently approved, and other novel agents (selepressin and terlipressin) are under investigation and used outside the United States (terlipressin).

Who the Included Studies Covered

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Findings from eligible literature are described qualitatively using Cochrane methods.

How the Review Was Done

Systematic review of controlled trials.

Numerous databases were searched using terms related to angiotensin II, selepressin, terlipressin, vasopressor, and shock.

Twenty-one citations, including 16 prospective comparative trials and 5 post hoc analyses reporting effects of AT2, selepressin, and terlipressin, were reviewed for data on outcomes related to hemodynamic measures, mortality, severity and duration of illness, concomitant vasopressor utilization, and adverse effects.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Arterial Pressure, Randomized Controlled Trials as Topic, Shock, Vasoconstrictor Agents and Vasopressins.

Author keywords: selepressin, sepsis, septic shock, systematic review, terlipressin and vasodilatory shock.

What This Means in Plain Language

This is a systematic review of Terlipressin and Angiotensin II.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of intensive care medicine), a journal based in United States.

More context: the Terlipressin compound page and the Angiotensin II compound page, all human trials.